Sensifree
Sensors for Contactless Heart Rate Monitoring
Company Overview
Snapshot
Founded in March 2012 by Eran Agmon and Ilan Barak, Sensifree operates with 1–10 employees. The company has raised $5 million across one funding round from three investors. In May 2016, Sensifree secured funding from investors including UMC Capital.
Business overview
Sensifree develops advanced blood pressure monitoring devices, focusing on cuff-free, comfortable, and discreet continuous monitoring. The company utilizes proprietary RF-based technology to generate unique signals from the radial artery, enabling evaluation of systolic and diastolic pressures. Sensifree aims to transform hypertension diagnosis and management, targeting clinics, home healthcare, and hospitals, with future expansion into consumer healthcare and bedside patient monitoring. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.
Strategic signal
In January 2018, Sensifree reported statistically significant concordance of arterial pressure signal waveform between its continuous non-invasive blood pressure monitoring technology and invasive arterial line. This validation underscores the accuracy and potential of Sensifree's technology for reliable, non-invasive vital sign monitoring, signaling a significant step towards broader clinical adoption and market trust in its innovative solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is Sensifree's primary focus?
- Sensifree is focused on developing the future of blood pressure monitoring devices by providing cuff-free, comfortable, and discreet continuous monitoring of this critical vital sign.
- When was Sensifree founded?
- Sensifree was founded in March 2012 by Eran Agmon and Ilan Barak.
- Which investors participated in Sensifree's funding round?
- In May 2016, Sensifree received funding from investors including UMC Capital.
- What significant research finding did Sensifree announce?
- In January 2018, Sensifree reported statistically significant concordance of arterial pressure signal waveform between its continuous non-invasive blood pressure monitoring technology and invasive arterial line.
- Did Sensifree engage in any strategic partnerships?
- In August 2020, Sensifree partnered with Dreamtech on product development, supported by the KORIL-RDF Foundation. Additionally, in January 2017, CSEM and Sensifree announced a research partnership.